SciSparc Advances $11.6M Pharma Portfolio Spin-Off Deal with Miza Ventures, Retaining 84% Control

SciSparc signs amended LOI for pharmaceutical spin-off valued at $11.6M, including clinical trials for Tourette syndrome, Alzheimer's, and...
19 hours ago
from: Stock Titan

Nasdaq, NasVax Ltd., Pharmaceutical industry, Publicly listed company

More about this

- SciSparc Provides Updates on Status of Spin-off of its
According to the LOI, SciSparc's pharmaceuticals assets are valued at approximately US$11.6 million TEL AVIV, Israel, Dec.
from: GlobeNewswire

- SciSparc amends non-binding LOI to spin-off advanced clinical stage portfolio
SciSparc (SPRC)has signed an amendment to its non-binding letter of intent to spin off by reverse merger its advanced clinical stage...
from: TipRanks